Global Blood and Blood-Forming Organs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

What is the Blood and Blood-Forming Organs Market Size and Growth Rate?

• As per Data Bridge Market Research analysis, the blood and blood-forming organs market was valued at USD 46.28 billion in 2025 and is projected to reach USD 65.81 billion by 2033, growing at a CAGR of 4.50% from 2026 to 2033.
• The market is experiencing consistent growth driven by the rising prevalence of blood disorders, increasing incidence of hematological malignancies, growing demand for advanced hematology therapies, and continuous advancements in biotechnology and personalized medicine.
• The increasing burden of anemia, thrombosis, hemophilia, and other blood-related disorders, combined with expanding access to specialized healthcare and innovative therapies, is encouraging healthcare providers to adopt advanced treatment approaches. Antithrombotic agents, antihemorrhagic preparations, antianemic preparations, blood substitutes, and other hematological agents remain important therapeutic categories within the market.

Market Size & Forecast

• Global Market Value (2025): USD 46.28 Billion
• Expected Market Value (2033): USD 65.81 Billion
• Forecast CAGR (2026–2033): 4.50%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

What are the Major Takeaways of the Blood and Blood-Forming Organs Market?

• North America dominated the blood and blood-forming organs market with the largest revenue share of 38.9% in 2025, supported by advanced healthcare infrastructure, established blood-bank networks, high healthcare expenditure, and strong adoption of automated blood collection and storage technologies.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 8.15% from 2026 to 2033, fueled by expanding healthcare infrastructure, increasing demand for blood and organ banking services, and growing investments in China, India, and Japan.
• The anemia and other erythrocyte disorders segment led the market with a 60% share in 2025, driven by the widespread prevalence of anemia across both developed and developing countries
• Sickle cell disease are the fastest-growing disease type, projected to register a CAGR of 6%, reflecting the surge in disease prevalence, improved diagnosis and newborn screening, growing awareness, and increasing demand for advanced therapies and transfusion support.
• The red blood cells segment dominated the product category with a 65.18% revenue share in 2025, led by their extensive use across surgery, trauma care, anemia management, cancer treatment, and chronic blood disorders.
• Trauma and surgery accounted for 45% of the market share in 2025, preferred by the extensive requirement for blood and blood components during surgical procedures and emergency treatment.
• The cancer treatment segment is the fastest-growing application category, with a CAGR of 6.76%, driven by rising incidence of cancer, increasing use of chemotherapy and radiotherapy, treatment-induced anemia and thrombocytopenia

Report Scope and Blood and Blood-Forming Organs Market Segmentation         

What is the Key Trend in the Blood and Blood-Forming Organs Market?

• Advanced blood-component processing and pathogen-reduction technologies are increasingly being adopted to improve transfusion safety, extend processing capabilities, and reduce the risk of transfusion-transmitted infections across blood banks and healthcare systems.
• For instance, in May 2025, the U.S. FDA updated the labeling for the INTERCEPT Blood System for Platelets, which uses amotosalen and UVA light to pathogen-reduce platelet components and reduce the risk of transfusion-transmitted infections, demonstrating continued adoption and regulatory support for advanced blood-component safety technologies
• The market is also shifting toward personalized blood management, with healthcare providers increasingly using patient-specific transfusion strategies, improved blood utilization monitoring, and advanced testing to minimize unnecessary transfusions and improve clinical outcomes.
• Growing adoption of plasma fractionation and specialized plasma-derived therapies is another important trend, particularly for immunoglobulins, albumin, coagulation factors, and treatments for inherited bleeding and immune disorders
• For instance, in June 2026, WHO reported that around 21.5 million litres of plasma from 36 reporting countries were fractionated for plasma-derived medicinal products, while only 49 of 168 reporting countries produced these products through domestic plasma fractionation, highlighting the growing importance of plasma collection and fractionation capacity for immunoglobulins, albumin, and coagulation products.
• As blood systems increasingly prioritize safety, component optimization, personalized transfusion practices, and plasma-derived therapies, technological modernization is expected to remain a central trend shaping the global blood and blood-forming organs market.

What are the Key Drivers of the Blood and Blood-Forming Organs Market?

• The rising prevalence of anemia, bleeding disorders, hematological malignancies, and inherited blood diseases is increasing demand for blood components, transfusion services, plasma-derived medicines, and specialized hematology treatments across healthcare systems.
• For instance, in December 2025, WHO reported that India’s annual blood collection increased from 12.6 million units in 2023 to 14.6 million units in 2024, with voluntary donations accounting for 74.55% of total collections. The increase reflects strengthening demand for blood services and expansion of national blood-collection capacity.
• Increasing surgical procedures, trauma care, cancer treatment, and chronic disease management are generating sustained requirements for red blood cells, platelets, plasma, and coagulation products, particularly in hospitals and specialized treatment centers.
• For instance, in June 2026, WHO reported that more than 120 million blood donations are collected globally each year, while significant disparities in blood availability remain between countries. The continued need for transfusion in surgery, trauma, cancer treatment, maternal care, and severe anemia supports sustained demand for blood and blood components
• Growing healthcare investment in emerging economies is also expanding blood-collection networks, testing laboratories, storage infrastructure, and plasma-processing capabilities, creating additional demand for blood and blood-forming organ products.

Which Factors are Challenging the Growth of the Blood and Blood-Forming Organs Market?

• Insufficient blood donations and significant regional disparities in blood availability remain major challenges, particularly in low-income and lower-middle-income countries where donation rates and blood-collection infrastructure remain substantially below high-income-country levels.
• For instance, in June 2025, WHO and Pakistan’s Ministry of Health reported a major blood-supply deficit: medical centres in Pakistan require more than 5 million blood donations annually, while only around 2.3 million donations were being received, highlighting the shortage of reliable blood supplies and collection infrastructure.
• Limited domestic plasma fractionation capacity and dependence on imported plasma-derived medicinal products can increase supply vulnerability, procurement costs, and treatment-access disparities for patients requiring immunoglobulins and coagulation factors.
• Advanced blood-screening, pathogen-reduction, storage, and processing technologies also require substantial investments in specialized equipment, skilled personnel, quality systems, and regulatory compliance, creating adoption barriers for resource-constrained healthcare systems.
• For instance, in June 2026, WHO reported that demand for safe blood and plasma-derived medicinal products continued to exceed supply in several countries, with only a limited number of countries possessing sufficient domestic plasma-fractionation capacity. This demonstrates persistent supply and infrastructure constraints affecting access to blood-derived therapies.
• These supply shortages, infrastructure limitations, unequal access, and high technology requirements continue to constrain market expansion, particularly across low- and middle-income countries where blood-system capacity remains comparatively limited.

How is the Blood and Blood-Forming Organs Market Segmented?

The blood and blood-forming organs market is segmented on the basis of disease, product, application, and end user.

• By Disease

On the basis of disease, the blood and blood-forming organs market is segmented into anemia and other erythrocyte disorders, coagulation defects and hemorrhagic disorders, sickle cell disease, thalassemia, hemophilia, diseases of the spleen, and other blood disorders. Anemia and other erythrocyte disorders dominated the disease segment, accounting for 60% share in 2025. The dominance is primarily attributable to the widespread prevalence of anemia across both developed and developing countries. Iron-deficiency anemia, anemia associated with chronic diseases, and treatment-related anemia generate substantial demand for blood-management and hematology services. Patients undergoing cancer treatment, surgery, dialysis, and treatment for chronic illnesses may also require management of anemia. Growing screening and diagnosis of blood disorders are improving identification of previously undiagnosed patients

The sickle cell disease segment is expected to be among the fastest-growing disease categories, with a CAGR of 6% over the forecast period. Sickle cell disease frequently requires specialized transfusion support, particularly for patients experiencing severe complications. Growing awareness and improved diagnosis are increasing the identified patient population in emerging markets. Advances in gene and cell therapies are also transforming the treatment landscape for sickle cell disease. Increasing investments in specialized hematology centers are improving access to disease management. The expansion of newborn screening programs is helping identify patients earlier in their disease course.

• By Product

On the basis of product, the market is segmented into whole blood, red blood cells, platelets, plasma, white blood cells, plasma-derived products, blood typing products, and blood screening products. Red blood cells dominated the product segment with a 65.18% share in 2025, owing to their extensive use across surgery, trauma care, anemia management, cancer treatment, and chronic blood disorders. Red blood cells have the broadest clinical application among transfusable blood components. Their demand is supported by both emergency and planned medical procedures. Increasing surgical volumes and trauma cases continue to require dependable red-cell inventories. Component-based transfusion practices further allow healthcare providers to target treatment toward patients requiring oxygen-carrying capacity.

The platelets segment is projected to be the fastest-growing product category at a CAGR of 6.50% through 2033. Increasing cancer incidence and the growing use of chemotherapy are creating greater demand for platelet transfusions. Hematopoietic stem-cell transplantation and advanced cellular therapies are also increasing platelet requirements. Platelets are particularly important for managing thrombocytopenia and preventing or controlling bleeding in high-risk patients. Advances in platelet collection, pathogen reduction, storage, and inventory management are improving product availability and safety. The short shelf life of platelets also creates continuous demand for efficient collection and distribution networks.

• By Application

On the basis of application, the market is segmented into anemia, trauma and surgery, cancer treatment, bleeding disorders, hemoglobinopathies, hematologic malignancies, coagulopathies, diagnostic applications, and research applications. Trauma and surgery dominated the application segment with 45% share in 2025, driven by the extensive requirement for blood and blood components during surgical procedures and emergency treatment. Major surgeries can involve substantial blood loss and therefore require immediate access to compatible blood products. Trauma centers also maintain significant blood inventories for emergency hemorrhage management. Increasing surgical volumes worldwide are creating sustained demand for transfusion services. Improvements in emergency medicine are further strengthening the need for rapidly available blood components.

The cancer treatment segment is projected to be the fastest-growing application category at a CAGR of 6.76% through 2033. Cancer patients frequently develop anemia and thrombocytopenia as a consequence of the disease or intensive treatment. Chemotherapy, radiation therapy, stem-cell transplantation, and other treatments can increase the need for transfusion support. The increasing incidence of cancer worldwide is therefore expanding the underlying patient pool requiring blood components. Growth in advanced hematologic cancer therapies is further increasing the need for supportive blood-management services. Platelets are particularly important for patients experiencing treatment-induced thrombocytopenia.

• By End User

On the basis of end user, the market is segmented into hospitals, blood banks, diagnostic laboratories, ambulatory surgical centers, specialty clinics, research institutes, and others. Hospitals dominated the end-user segment with a 68.19% share in 2025, owing to their central role in emergency care, surgery, oncology, intensive care, and complex hematology treatment. Hospitals maintain continuous access to blood banks and transfusion services because critically ill patients may require immediate blood-component availability. Surgical departments represent a major source of transfusion demand within hospitals. Oncology and hematology departments also require regular access to red blood cells and platelets. Hospitals In addition provide the laboratory infrastructure required for blood grouping, cross-matching, compatibility testing, and transfusion monitoring.

The ambulatory surgical centers segment is projected to be the fastest-growing end-user category at a CAGR of 6.55% through 2033. The expansion of minimally invasive and same-day surgical procedures is shifting selected procedures from inpatient hospitals toward ambulatory settings. As procedure volumes increase, ASCs require appropriate blood-management and transfusion-preparedness capabilities. Improvements in surgical techniques are allowing increasingly complex procedures to be performed in outpatient environments. Healthcare providers are also using ASCs to improve operational efficiency and reduce hospitalization-related costs. The growing outpatient surgical infrastructure is therefore creating additional demand for blood-component availability outside conventional hospitals.

Which Region Holds the Largest Share of the Blood and Blood-Forming Organs Market?

• North America dominated the blood and blood-forming organs market with the largest revenue share of 38.9% in 2025, supported by advanced healthcare infrastructure, established blood-bank networks, high healthcare expenditure, and strong adoption of automated blood collection and storage technologies.
• The region also benefits from advanced healthcare systems, stringent blood-safety standards, sophisticated blood management practices, and continued investments in automated collection and processing technologies. Growing demand for transfusion services in trauma care, surgery, cancer treatment, and chronic disease management further strengthens North America’s leadership position in the global market.

U.S. Blood and Blood-Forming Organs Market Insight

The U.S. blood and blood-forming organs market is witnessing strong growth due to rising demand for blood transfusions, advanced blood-component therapies, and well-established blood collection and processing infrastructure. The country’s mature healthcare system, along with increasing adoption of automated blood screening, component separation, and transfusion-management technologies, is driving demand across hospitals, blood banks, and specialized care facilities. In addition, growing prevalence of cancer, anemia, trauma-related conditions, and surgical procedures is accelerating the need for reliable blood and blood-component supplies.

Asia-Pacific Blood and Blood-Forming Organs Market Insight

The Asia-Pacific blood and blood-forming organs market is expected to witness rapid growth, driven by increasing healthcare expenditure, expanding hospital infrastructure, and rising demand for safe blood transfusion services across countries such as China, India, and Japan. Growing awareness regarding voluntary blood donation, improvements in blood-screening practices, and increasing adoption of advanced collection and processing technologies are supporting regional market expansion. In addition, rising incidence of cancer, anemia, and other blood disorders is accelerating demand for blood components and transfusion services across emerging healthcare systems.

Japan Blood and Blood-Forming Organs Market Insight

The Japan blood and blood-forming organs market is witnessing consistent growth due to rising demand for safe transfusion services, advanced blood-processing technologies, and sophisticated healthcare infrastructure. Hospitals, blood centers, and specialized healthcare facilities are increasingly adopting automated screening, component separation, and transfusion-management technologies to improve blood safety and clinical outcomes. Moreover, the country’s aging population, increasing prevalence of chronic diseases, and focus on efficient healthcare delivery are further contributing to market growth in Japan.

China Blood and Blood-Forming Organs Market Insight

The China blood and blood-forming organs market is growing rapidly, driven by expanding healthcare infrastructure, increasing demand for transfusion services, and rising government focus on blood safety and voluntary donation programs. Growing adoption of advanced blood collection, screening, storage, and processing technologies across hospitals and blood centers is significantly boosting market demand. In addition, rising prevalence of cancer, anemia, trauma, and surgical procedures, along with improvements in healthcare accessibility, is positioning China as one of the fastest-growing markets for blood and blood-forming organ-related products and services globally.

U.K. Blood and Blood-Forming Organs Market Insight

The U.K. blood and blood-forming organs market is experiencing steady growth, supported by established blood donation networks, advanced transfusion services, and increasing adoption of sophisticated blood-processing technologies. Growing investments in blood safety, pathogen screening, component management, and digital transfusion systems are contributing to market growth. Furthermore, rising demand for blood products in surgery, cancer treatment, trauma care, and hematological disorders is strengthening the U.K. market and supporting continued development of its blood and transfusion infrastructure.

Germany Blood and Blood-Forming Organs Market Insight

The Germany blood and blood-forming organs market is expanding steadily due to the country’s advanced healthcare infrastructure, strong blood-donation system, and increasing adoption of next-generation transfusion technologies. Hospitals, blood centers, and clinical laboratories are increasingly utilizing automated screening, blood-component processing, and digital monitoring systems to enhance safety and efficiency. Continuous advancements in transfusion medicine, growing demand for blood products in surgery and cancer care, and strong emphasis on blood safety and quality are further driving market growth in Germany.

Which are the Top Companies in Blood and Blood-Forming Organs Market?

The blood and blood-forming organs industry is primarily led by well-established companies, including:

• Terumo BCT, Inc. (U.S.)
• Haemonetics Corporation (U.S.)
• Macopharma (France)
• Grifols, S.A. (Spain)
• Octapharma AG (Switzerland)
• CSL (Australia)
• Werfen (Spain)
• Bio-Rad Laboratories, Inc. (U.S.)
• Beckman Coulter, Inc. (U.S.)
• Sysmex (Japan)
• Fresenius Kabi AG (Germany)
• Cerus Corporation (U.S.)
• Abbott (U.S.)
• BD (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• ADMA Biologics, Inc. (U.S.)
• Kedrion S.p.A. (Italy)
• Kamada Ltd. (Israel)

What are Latest Developments in Blood and Blood-Forming Organs Market?

• In November 2025, the U.S. FDA cleared eTraceLine/P.H.S., a transfusion-service management software platform developed by MAK-SYSTEM Group, designed to support blood-component preparation, testing, inventory tracking, compatibility testing, transfusion records, and patient identification. The platform integrates with hospital and laboratory information systems and blood-storage devices, helping transfusion services improve traceability, workflow efficiency, and patient safety. This development highlights the increasing digitalization of blood-bank and transfusion-management operations.
• In May 2024, the U.S. FDA approved the INTERCEPT Blood System for Cryoprecipitated Fibrinogen Complex, a pathogen-reduced blood component intended for the treatment and control of bleeding, including massive hemorrhage. The technology uses pathogen-reduction processing to improve the safety profile of a blood-derived product while supporting its use in patients requiring fibrinogen replacement. The approval represents continued advancement in pathogen-reduction technologies for blood components and supports the development of safer transfusion products.
• In December 2023, the U.S. FDA approved Casgevy, the first FDA-approved therapy utilizing CRISPR/Cas9 genome editing, for patients with sickle cell disease aged 12 years and older with recurrent vaso-occlusive crises. The treatment uses genetically modified blood stem cells to increase fetal hemoglobin production and reduce the complications associated with sickle cell disease. This milestone expanded the role of advanced cellular and genetic therapies in the treatment of blood-forming disorders. FDA announcement on Casgevy and Lyfgenia
• In June 2022, the World Health Organization released its Global Status Report on Blood Safety and Availability 2021, providing an updated assessment of blood collection, testing, processing, and clinical transfusion practices worldwide. The report highlighted progress toward nationally coordinated blood-transfusion services and assessed countries’ ability to make quality-assured plasma available for fractionation into plasma-derived medicinal products. The publication reinforced the importance of strengthening national blood systems and improving access to safe blood and plasma products.
• In March 2021, the World Health Organization issued guidance on increasing supplies of plasma-derived medicinal products in low- and middle-income countries through fractionation of domestic plasma. The guidance outlined approaches for strengthening domestic plasma collection and fractionation capacity and improving access to essential plasma-derived therapies. This initiative supported efforts to reduce shortages, strengthen national blood-product systems, and increase the availability of quality-assured plasma-derived medicinal products in underserved markets